1217302-63-0

Basic information

• Product Name: ethoxy-N-[2-iodo-4-(trifluoromethyl)phenyl]carboxamide
• Synonyms: ethoxy-N-[2-iodo-4-(trifluoromethyl)phenyl]carboxamide
• CAS NO: 1217302-63-0
• Molecular Weight: 359.087
• Mol File: 1217302-63-0.mol

Chemical Properties

• Boiling Point: 279.0±40.0 °C(Predicted)
• Density: 1.786±0.06 g/cm3(Predicted)
• CAS DataBase Reference: ethoxy-N-[2-iodo-4-(trifluoromethyl)phenyl]carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: ethoxy-N-[2-iodo-4-(trifluoromethyl)phenyl]carboxamide(1217302-63-0)
• EPA Substance Registry System: ethoxy-N-[2-iodo-4-(trifluoromethyl)phenyl]carboxamide(1217302-63-0)

Safety Data

• Hazardous Substances Data: 1217302-63-0(Hazardous Substances Data)

Upstream product

• 79-22-1 methyl chloroformate 
• 163444-17-5 2-iodo-4-(trifluoromethyl)aniline 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 1217302-64-1 N-[2-(3,3-dimethyl-3-silabut-1-ynyl)-4-(trifluoromethyl)phenyl]ethoxycarboxamide 
• 100846-24-0 5-trifluoromethyl-1H-indole 
• 898748-27-1 6-trifluoromethylbenzothiazol-2-one 
• 1242622-39-4 C₂₂H₁₈F₃N₃O 
• 1242622-36-1 C₂₂H₂₇F₃N₂O₄ 

Relevant articles and documents

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM

The present invention discloses novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), a pharmaceutically acceptable salt or a sol

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.